INMED PHARMACEUTICALS INC. Increase (Decrease) in Accounts Receivable
INMED PHARMACEUTICALS INC. (INM) reported Increase (Decrease) in Accounts Receivable of -$282.14 thousand for the 6-month period ending 2025-12-31, per its 10-Q filed 2026-02-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-07-02
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$159.98K.
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$122.16K.
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts receivable for the quarter ending 2025-06-30 was $99.72K, a 31.31% decline year-over-year.
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts receivable for the quarter ending 2025-03-31 was $105.24K.
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts receivable for fiscal 2023 was $219.15K, a 447.76% increase from fiscal 2022.
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts receivable for fiscal 2022 was $40.01K.
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts receivable for fiscal 2021 was -$40.20K.
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts receivable for fiscal 2020 was -$17.27K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 3 month as first filed | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | -$159.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | -$282.14K 10-Q · filed 2026-02-11 | -$182.42K derived: sum of 3 quarters · filed 2026-07-02 | -$77.18K derived: sum of 4 quarters · filed 2026-07-02 | |
| 2025-09-30 | -$122.16K 10-Q · filed 2025-11-06 | -$22.45K derived: sum of 2 quarters · filed 2026-07-02 | $82.80K derived: sum of 3 quarters · filed 2026-07-02 | $60.15K derived: sum of 4 quarters · filed 2026-07-02 | |
| 2025-06-30 | $99.72K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $204.96K derived: sum of 2 quarters · filed 2026-07-02 | $182.31K derived: sum of 3 quarters · filed 2026-07-02 | $114.69K S-4 · filed 2026-07-02 | |
| 2025-03-31 | $105.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $82.60K derived: sum of 2 quarters · filed 2026-02-11 | $14.97K 10-Q · filed 2025-05-12 | $160.13K derived: sum of 4 quarters · filed 2026-07-02 | |
| 2024-12-31 | -$22.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | -$90.27K 10-Q · filed 2026-02-11 | $54.89K derived: sum of 3 quarters · filed 2026-07-02 | -$110.30K derived: sum of 4 quarters · filed 2026-07-02 | |
| 2024-09-30 | -$67.62K 10-Q · filed 2025-11-06 | -$68.14K 10-Q · filed 2024-11-14 | $77.53K derived: sum of 2 quarters · filed 2026-07-02 | -$87.66K derived: sum of 3 quarters · filed 2026-07-02 | $119.36K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-06-30 | $145.16K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | -$20.03K derived: sum of 2 quarters · filed 2026-07-02 | $186.99K derived: sum of 3 quarters · filed 2026-07-02 | $92.44K S-4 · filed 2026-07-02 | |
| 2024-03-31 | -$165.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $41.83K derived: sum of 2 quarters · filed 2025-05-12 | -$52.72K 10-Q · filed 2025-05-12 | $59.07K derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $207.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $112.47K 10-Q · filed 2025-02-12 | $224.26K derived: sum of 3 quarters · filed 2025-02-12 | $312.91K derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-09-30 | -$94.55K 10-Q · filed 2024-11-14 | $17.24K derived: sum of 2 quarters · filed 2024-11-14 | $105.89K derived: sum of 3 quarters · filed 2024-11-14 | $197.46K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $111.79K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $200.44K derived: sum of 2 quarters · filed 2024-09-30 | $292.00K derived: sum of 3 quarters · filed 2024-09-30 | $219.15K 10-K · filed 2024-09-30 | |
| 2023-03-31 | $88.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $180.22K derived: sum of 2 quarters · filed 2024-02-13 | $107.36K 10-Q · filed 2023-05-15 | $124.83K derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-12-31 | $91.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | $18.70K 10-Q · filed 2024-02-13 | $36.18K derived: sum of 3 quarters · filed 2024-02-13 | $56.43K derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-09-30 | -$72.86K 10-Q · filed 2023-11-14 | -$55.38K derived: sum of 2 quarters · filed 2023-11-14 | -$35.13K derived: sum of 3 quarters · filed 2023-11-14 | -$35.77K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $17.47K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $37.72K derived: sum of 2 quarters · filed 2023-09-29 | $37.09K derived: sum of 3 quarters · filed 2023-09-29 | $40.01K 10-K · filed 2023-09-29 | |
| 2022-03-31 | $20.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $19.61K derived: sum of 2 quarters · filed 2023-05-15 | $22.54K 10-Q · filed 2023-05-15 | -$35.85K derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | -$638.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-17 | $2.29K 10-Q · filed 2023-02-17 | -$56.10K derived: sum of 3 quarters · filed 2023-02-17 | -$140.64K derived: sum of 4 quarters · filed 2023-02-17 | |
| 2021-09-30 | $2.92K 10-Q · filed 2022-11-14 | -$55.46K derived: sum of 2 quarters · filed 2022-11-14 | -$140.00K derived: sum of 3 quarters · filed 2022-11-14 | -$42.83K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$58.38K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | -$142.93K derived: sum of 2 quarters · filed 2022-09-23 | -$45.75K derived: sum of 3 quarters · filed 2022-09-23 | -$40.20K 10-K · filed 2022-09-23 | |
| 2021-03-31 | -$84.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | $12.63K derived: sum of 2 quarters · filed 2022-05-13 | $18.18K 10-Q · filed 2022-05-13 | $30.61K derived: sum of 4 quarters · filed 2022-05-13 | |
| 2020-12-31 | $97.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $102.73K 10-Q · filed 2022-02-14 | $115.16K derived: sum of 3 quarters · filed 2022-02-14 | ||
| 2020-09-30 | $5.55K 10-Q · filed 2021-11-10 | $17.98K derived: sum of 2 quarters · filed 2021-11-10 | |||
| 2020-06-30 | $12.43K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | -$17.27K 10-K · filed 2021-09-24 | |||
| 2020-03-31 | -$29.70K 10-Q · filed 2021-05-13 | ||||
| 2019-09-30 | -$34.00K 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |